Compared with repaglinide, sulfonylurea treatment in type 2 diabetes is associated with a 2.5-fold increase in symptomatic hypoglycemia with blood glucose levels - 45 mg/dl (Abstract) - Kristensen, J S; Frandsen, K B; Bayer, T; Muller, P (Diabetes, 2000)